The future of precision medicine starts here
Our mission is to develop targeted microbiome-based therapeutics and molecular diagnostic tools to prevent and treat diseases of high unmet medical needs
See Our Pipeline
Harnessing the power of microbiome-based therapeutics
Siolta Therapeutics is a clinical-stage biopharmaceutical company developing targeted microbiome-based therapeutics to prevent and treat diseases of high unmet medical need. By leveraging our proprietary Precision Symbiotics Platform™ and Live Biotherapeutics Products (LBPs) GMP-manufacturing capabilities, we are rapidly expanding our product pipeline across multiple indications with multiple programs in preclinical and clinical-stage development.
Our Proprietary Platform
Publications
Microbial Genomics
Finding the right fit: evaluation of short-read and long-read sequencing approaches to maximize the utility of clinical microbiome data
Read More
News
Siolta Therapeutics awarded NIH grant funding
Advance Technology Small Business Innovation Grant Award from NIAID
Read More
News
Siolta Collaboration with Bio-Me
Microbiome-based Prognostics for Early Identification of Allergy and Asthma
November 23, 2020
Read More